Effect of prior pharmacotherapy on remission with sequential bilateral theta-burst versus standard bilateral repetitive transcranial magnetic stimulation in treatment-resistant late-life depression.
Rafae A WathraBenoit H MulsantZafiris J DaskalakisJonathan DownarShawn M McClintockSean M NestorTarek K RajjiAlisson P TrevizolDaniel M BlumbergerPublished in: The British journal of psychiatry : the journal of mental science (2023)
Repetitive transcranial magnetic stimulation (rTMS) is used for treatment of late-life depression. In the FOUR-D study, sequential bilateral theta-burst stimulation (TBS) had comparable remission rates to standard bilateral rTMS. Data were analysed from the FOUR-D trial to compare remission rates between two types of rTMS based on the number and class of prior medication trials. The remission rate was higher in participants with ≤1 previous trial (43.9%) than in participants with 2 previous trials (26.5%) or ≥3 previous trials (24.6%; χ² = 6.36, d.f. = 2, P = 0.04). Utilising rTMS earlier in late-life depression may lead to better outcomes.
Keyphrases
- transcranial magnetic stimulation
- high frequency
- disease activity
- depressive symptoms
- ulcerative colitis
- case report
- sleep quality
- study protocol
- phase iii
- clinical trial
- systemic lupus erythematosus
- rheumatoid arthritis
- type diabetes
- emergency department
- adipose tissue
- big data
- randomized controlled trial
- insulin resistance
- machine learning
- skeletal muscle
- artificial intelligence
- deep learning